Generic TPOXX Availability
Last updated on Aug 7, 2024.
TPOXX is a brand name of tecovirimat, approved by the FDA in the following formulation(s):
TPOXX (tecovirimat - capsule;oral)
-
Manufacturer: SIGA TECHNOLOGIES
Approval date: July 13, 2018
Strength(s): 200MG [RLD]
TPOXX (tecovirimat - solution;intravenous)
-
Manufacturer: SIGA TECHNOLOGIES
Approval date: May 18, 2022
Strength(s): 200MG/20ML (10MG/ML) [RLD]
Has a generic version of TPOXX been approved?
No. There is currently no therapeutically equivalent version of TPOXX available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of TPOXX. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
ST-246 liquid formulations and methods
Patent 10,576,165
Issued: March 3, 2020
Inventor(s): Tyavanagimatt Shanthakumar R. & Anderson Melialani A. C. L. S. & Weimers William & Kasi Gopi Krishna & Samuel N K Peter & Bolken Tove C. & Hruby Dennis E.
Assignee(s): Siga Technologies Inc.The present invention provides for a novel liquid formulation for solubilizing poorly soluble ST-246 in cyclodextrins and a novel process of making the formulation.
Patent expiration dates:
- August 2, 2031✓
- August 2, 2031
-
Patent 11,890,270
Patent expiration dates:
- August 8, 2032✓
- August 8, 2032
-
Patent 7,737,168
Patent expiration dates:
- September 4, 2031✓
- September 4, 2031✓
- September 4, 2031
-
Patent 8,039,504
Patent expiration dates:
- July 23, 2027✓
- July 23, 2027
-
Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases
Patent 8,124,643
Issued: February 28, 2012
Inventor(s): Jordan Robert & Bailey Thomas R. & Rippin Susan R.
Assignee(s): Siga Technologies, Inc.Methods of using di, tri, and tetracyclic acylhydrazide derivatives and analogs, as well as pharmaceutical compositions containing the same, for the treatment or prophylaxis of viral infections and diseases associated therewith, particularly those viral infections and associated diseases caused by the orthopoxvirus.
Patent expiration dates:
- June 18, 2024✓✓
- June 18, 2024
-
Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases
Patent 8,530,509
Issued: September 10, 2013
Inventor(s): Jordan Robert & Bailey Thomas R. & Rippin Susan R. & Dai Dongcheng
Assignee(s): Siga Technologies, Inc.Methods of using di, tri, and tetracyclic acylhydrazide derivatives and analogs, as well as pharmaceutical compositions containing the same, for the treatment or prophylaxis of viral infections and diseases associated therewith, particularly those viral infections and associated diseases caused by the orthopoxvirus.
Patent expiration dates:
- June 18, 2024✓
- June 18, 2024
-
Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases
Patent 8,802,714
Issued: August 12, 2014
Inventor(s): Jordan Robert F. & Bailey Thomas R. & Rippin Susan R. & Dai Dongcheng
Assignee(s): Siga Technologies, Inc.Methods of using di, tri, and tetracyclic acylhydrazide derivatives and analogs, as well as pharmaceutical compositions containing the same, for the treatment or prophylaxis of viral infections and diseases associated therewith, particularly those viral infections and associated diseases caused by the orthopoxvirus.
Patent expiration dates:
- June 18, 2024✓
- June 18, 2024
-
ST-246 liquid formulations
Patent 9,233,097
Issued: January 12, 2016
Inventor(s): Tyavanagimatt Shanthakumar R. & Stone Melialani A. C. L. & Weimers William C. & Kasi Gopi Krishna & Samuel Peter N. K. & Bolken Tove & Hruby Dennis E.
Assignee(s): SIGA TECHNOLOGIES, INC.The present invention provides for a novel liquid formulation for solubilizing poorly soluble ST-246 in cyclodextrins and a novel process of making the formulation.
Patent expiration dates:
- August 2, 2031✓
- August 2, 2031
-
Polymorphic forms of ST-246 and methods of preparation
Patent 9,339,466
Issued: May 17, 2016
Inventor(s): Tyavanagimatt Shanthakumar R. & Stone Melialani A. C. L. & Weimers William C. & Nelson Dylan & Bolken Tove′ C. & Hruby Dennis E. & "ONeill Michael H." & Sweetapple Gary & McCloughan Kelley A.
Assignee(s): SIGA TECHNOLOGIES, INC.Polymorph forms of 4-trifluoromethyl-N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop[f]isoindol-2(1H)-yl)-benzamide are disclosed as well as their methods of synthesis and pharmaceutical compositions.
Patent expiration dates:
- March 23, 2031✓✓
- March 23, 2031
-
ST-246 liquid formulations and methods
Patent 9,907,859
Issued: March 6, 2018
Inventor(s): Tyavanagimatt Shanthakumar R. & Anderson Melialani A. C. L. S. & Weimers William & Kasi Gopi Krishna & Samuel N K Peter & Bolken Tove′ C. & Hruby Dennis E.
Assignee(s): Siga Technologies, Inc.The present invention provides for a novel liquid formulation for solubilizing poorly soluble ST-246 in cyclodextrins and a novel process of making the formulation.
Patent expiration dates:
- August 2, 2031✓
- August 2, 2031
Related exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
Exclusivity expiration dates:
- July 13, 2025 - INDICATED FOR THE TREATMENT OF HUMAN SMALLPOX DISEASE CAUSED BY VARIOLA VIRUS IN ADULTS AND PEDIATRIC PATIENTS WEIGHING AT LEAST 13 KG
More about TPOXX (tecovirimat)
- Check interactions
- Compare alternatives
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: miscellaneous antivirals
- Breastfeeding
- En español
Patient resources
Professional resources
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
